Lakewood-Amedex Biotherapeutics Inc. Cost of Revenue
Lakewood-Amedex Biotherapeutics Inc. (LABT) reported Cost of Revenue of $507.29 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-22.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-05-22
- Lakewood-Amedex Biotherapeutics Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $507.29K.
| Period end | Cost of Goods and Services Sold 3 month |
|---|---|
| 2026-03-31 | $507.29K 10-Q · filed 2026-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B |